Phase 3 Bladder Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been newly diagnosed with a specific type of kidney/urinary tract cancer (high-grade urothelial carcinoma) that has been confirmed by a scan, urine test, or biopsy, and has not spread to lymph nodes or other parts of the body
- You are 18 years of age or older
- You are generally active and able to carry out daily activities with little or no limitation (confirm with trial site)
- Your doctors have decided that surgery to remove the kidney and ureter (or ureter alone) is a suitable option for you
- Your doctors have decided that a chemotherapy treatment containing cisplatin is a suitable option for you
- Your blood counts, liver function, electrolyte levels, and kidney function are all within acceptable ranges as determined by blood tests (confirm with trial site)
Who may not be able to join:
- Your cancer has already spread to other parts of the body (metastatic disease)
- Scans show cancer has spread to your lymph nodes
- You also have muscle-invasive bladder cancer at the same time (having non-muscle-invasive bladder cancer is acceptable)
- You only have one kidney
- You have been diagnosed with another cancer, or received systemic chemotherapy, within the last 2 years (previous bladder cancer or certain bladder treatments are still acceptable)
- You have certain existing health conditions that make cisplatin chemotherapy unsafe for you, such as significant hearing loss, moderate-to-severe nerve damage, or a serious active infection
- You are currently taking part in another clinical drug trial
- You are pregnant or breastfeeding — and if you join, you must use contraception, avoid fathering a child, and not donate sperm during treatment and for 6 months after the last dose
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Girish Kulkarni, MD, University Health Network - Princess Margaret Hospital
Phone: (416) 270-5395
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Feasibility of enrolling cT1-4N0 M0 UTUC patients in a randomized trial of neoadjuvant chemotherapy versus standard of care by assessing pilot trial recruitment rates; Disease-free survival (DFS); Rate of complete pathologic response
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.